LONG-TERM EFFECT OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS ON THE PRODUCTION OF CYTOKINES AND OTHER INFLAMMATORY MEDIATORS BY BLOOD-CELLS OF PATIENTS WITH OSTEOARTHRITIS
E. Gonzalez et al., LONG-TERM EFFECT OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS ON THE PRODUCTION OF CYTOKINES AND OTHER INFLAMMATORY MEDIATORS BY BLOOD-CELLS OF PATIENTS WITH OSTEOARTHRITIS, Agents and actions, 41(3-4), 1994, pp. 171-178
Most of the previous studies dealing with the effect of nonsteroidal a
nti-inflammatory drugs (NSAIDs) on the synthesis of inflammatory media
tors involved in joint damage have been done in cells cultured in vitr
o or in blood cells from patients treated for short periods of time. I
n this work we have evaluated the long-term effect of aceclofenac, a n
ew NSAID, and diclofenac on the production of a series of inflammatory
mediators by blood cells from 30 patients with severe knee osteoarthr
itis. Both aceclofenac and diclofenac significantly inhibited prostagl
andin E2 (PGE2) synthesis by blood mononuclear and polymorphonuclear c
ells after 180 days of treatment. However, no clear effect was noted o
n leukotriene B4 (LTB4) and platelet activating factor (PAF) productio
n. The generation of O-2(-), by polymorphonuclear cells, stimulated wi
th FMLP, was decreased after 15 days of treatment with both drugs, but
reached normal values after 180 days. Interleukin-1 beta (IL-1 beta)
production decreased significantly at 180 days with both drugs in the
group of high producer patients. In a few (n = 3) patients with high b
asal mononuclear cell tumor necrosis factor a (TNF alpha) production,
this also decreased on treatment for 180 days with the NSAIDs. In the
remaining low TNF alpha-producing patients, TNF alpha production tende
d to increase. Interleukin-6 (IL-6) synthesis was not affected by acec
lofenac while it was diminished by diclofenac. The decrease in IL-6 in
all treated patients was significantly correlated with a worsening of
the clinical condition. On the whole, these data could afford a patho
genetic basis for the long-term employment of these drugs in patients
with inflammatory conditions.